MARKETS
Distinct global contexts. A unified platform.
Adaptive commercial pathways
Medical Ethics operates a single integrated platform, deployed across two structurally different livestock market environments. The product is the same. The regulatory drivers, purchasing logic, and value creation pathways differ materially.
REGION 1
Africa · Asia · Mekong · South-East Asia
FMD & endemic disease markets
In FMD-endemic regions, Tri-Solfen® functions as a disease recovery and productivity restoration tool embedded within national and donor-led animal health programmes. It is positioned as a complementary intervention, alongside vaccination and biosecurity, that restores functional productivity after outbreak impact.
Core role in system
Closing the analgesic gap in FMD outbreak response
FMD lesions produce severe, sustained nociception at oral and interdigital sites. Animals in acute pain cease eating and restrict movement, the productivity consequences of unmanaged pain are often greater than those of the infection itself.
Solfen-Tech closes the analgesic gap at the lesion site: 30-second onset anaesthesia, sustained through the wound depot mechanism, restores eating behaviour within 48 hours and mobility within 72 hours. Cetrimide prevents secondary infection, interrupting the cascade that would otherwise perpetuate the pain and productivity loss cycle, whilst supporting antimicrobial stewardship objectives.
For farmers and disease programme veterinarians, this delivers an immediate, visible recovery outcome that is impossible to attribute to vaccination or biosecurity alone. This visibility drives farmer compliance, converting disease control from abstract policy instruction into tangible, farm-level benefit.
Strategic importance
FMD causes an estimated USD 21 billion in annual production losses and vaccination costs in endemic regions alone, with
the true economic burden considerably higher when trade
disruption is included — FAO, 2025.
In this context, pain mitigation is not ancillary—it is a
productivity restoration intervention within national food
security systems.
Primary stakeholders
- Ministries of Agriculture / Veterinary Services
- Food and Agriculture Organization
- Disease control programmes and donor agencies
- Field veterinarians and extension networks
REGION 2
Europe · Australia & New Zealand · Americas
Procedural livestock markets
In developed livestock systems, the commercial driver is not
disease burden—it is regulatory compliance, retailer enforcement, and social licence to operate.
Pain mitigation is transitioning from best practice to mandatory production standard.
Core role in system
Full-spectrum pain coverage as a compliance standard
In procedural livestock markets, the clinical standard is converging on combined local anaesthesia and systemic analgesia for all invasive procedures. The scientific basis for this standard is the analgesic gap: systemic NSAIDs do not reach therapeutic concentrations at the time of injury, leaving the acute nociceptive phase uncovered.
Solfen-Tech closes this gap with 30-second onset topical anaesthesia, sustained through the wound depot mechanism. Used alongside an NSAID, it delivers complementary phase coverage: Tri-Solfen addresses the acute nociceptive phase, the NSAID addresses the systemic inflammatory phase. Neither mechanism overlaps. Together, they produce outcomes that neither achieves alone, faster wound healing, improved weight gain, reduced mortality, and improved maternal behaviour.
This combination is what regulators, assurance schemes, and major retailers are increasingly requiring. Solfen-Tech is the only topical anaesthetic with the regulatory-grade evidence base to meet this standard across multiple species and jurisdictions.
Strategic importance
In these markets, adoption is not driven by clinical need
alone—it is driven by:
- auditability
- compliance certainty
- supply chain enforcement
- reputational risk management
Primary stakeholders
- Regulators
- Retailers and processors
- Assurance schemes
- Veterinarians
- Commercial producers
GLOBAL APPROVAL FOOTPRINT
Regulatory validation across global livestock systems
For Medical Ethics, regulatory approvals are the mechanism that converts welfare science into enforceable market access. Tri-Solfen® is currently approved or registered across multiple international jurisdictions, backed by an active pipeline of ongoing dossiers designed to secure further structural integration worldwide.
This footprint reflects a phased, highly strategic rollout. In Australia and New Zealand, the platform has already reached fully established commercial adoption, serving as the commercial proof of concept. From this foundation, we are executing a regulated expansion phase throughout the UK and Europe, alongside a targeted, FMD-driven deployment corridor across Asia and Africa. Simultaneously, we are accelerating procedural approvals throughout the Americas, ensuring our standard-setting position continues to scale globally.
Country
Lambs
Calves
Piglets
Horses
Australia
New Zealand
United Kingdom
Portugal
Canada
Brazil
Mexico
Kenya
Laos
European Union (Piglet dossier in progress)
Indonesia
Uganda
United States (in development)
Licensing Model
Capital-light global expansion architecture
Medical Ethics operates a licensing-led commercial model, designed to convert regulatory approvals directly into monetizable market access.
We do not build large-scale sales infrastructure. Instead, regulatory approval defines the asset; licensing converts it into revenue.
The Value Creation Sequence
Regulatory access creates exclusive, jurisdiction-specific market rights.
Licensing execution allows partners to secure commercialization rights within defined territories.
Commercial rollout is executed by partners under strictly governed brand and claims frameworks.
Revenue capture yields structured returns across three channels: upfront execution fees, milestone payments tied to commercial triggers, and recurring royalties on net sales.
The Strategic Advantage
This model ensures capital-light scaling and partner-driven distribution leverage. By generating recurring, compounding royalty streams, our regulatory moat serves as the ultimate barrier to entry.
As welfare standards tighten globally, regulatory approval becomes the binding constraint to market entry, structurally increasing the value of each licensed jurisdiction.
The Investment Logic: A Dual-Market Platform
Medical Ethics operates across two structurally distinct, yet highly complementary, demand systems. In FMD-endemic regions, adoption is driven by disease recovery, food security, and donor initiatives. In procedural markets, demand is dictated by regulatory enforcement, retailer compliance, and mandated welfare standards.
Both systems converge on a single, powerful outcome. FMD regions initiate rapid system recovery and adoption, while procedural markets provide regulatory enforcement and stable scale. Our licensing model converts both pathways into capital-light, recurring revenue streams—transforming regulatory approval into mandated protocol, and protocol into compounding yield.
For detailed financial information and investor enquiries, please contact our executive team.